1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
T&R Biofab Co., Ltd

T&R Biofab Co., Ltd

KKRX:246710
1,970.00
KRW
-35.00
(-1.75%)
-683.16EPS
98.22BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
8.31
56.53
19.28
21.57
46.8
51.32
268.9
60.21
234.03
207.87
124.8
843.45
806.92
Basic EPS, GAAP
-693.73
-959.02
-212.31
-215.82
-225.42
-249.26
-221.45
-1,304.22
-420.39
-536.51
-196.63
-999.32
-683.16
Free Cash Flow per Basic Share
-670.5
-918.43
-227.4
-209.71
-297.03
-234.53
-416.43
-309.02
-688.16
-787.36
-372.35
-308.62
-120.65
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
10.61
187.46
464.04
475.64
1,575.36
1,256.83
2,264.75
1,721.66
1,570.12
1,228.48
952.36
548.11
445.79
Tangible Book Value per Share
0.11
177.76
448.16
461.98
1,560.64
1,239.91
2,228.57
1,688.71
1,536.11
1,195.74
900.07
524
421.66
Basic Weighted Avg Shares
1
1
14
19
21
25
25
54
25
25
39
32
41
Sales/Revenue/Turnover
6
73
274
406
974
1,287
6,805
3,235
5,755
5,199
4,874
26,967
32,732
Operating Margin (%)
-8,141.9
-1,521.59
-1,130.65
-1,025.58
-506.39
-532.94
-80.95
-316.91
-221.1
-243.36
-272.87
-31.78
-15.22
Depreciation Expense
23
48
132
175
247
814
1,269
1,743
1,948
2,156
2,404
5,034
4,897
Net Income, GAAP
-496
-1,240
-3,020
-4,058
-4,693
-6,251
-5,604
-70,068
-10,337
-13,419
-7,679
-31,951
-27,712
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-8,347.39
-1,696.46
-1,101.3
-1,000.66
-481.71
-485.66
-82.36
-2,166.15
-179.63
-258.1
-157.55
-118.48
-84.66
Working Capital
2,022
1,289
7,702
8,097
29,839
21,978
41,625
59,309
17,732
6,609
-14,552
4,496
-36,147
LT Debt
50
- -
- -
- -
- -
650
498
14,374
6,713
16,703
20,980
23,277
16,248
Total Equity
202
3,575
8,850
9,071
30,266
24,757
46,052
42,107
39,263
31,197
24,211
26,071
21,204
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-65.66
-48.61
-45.29
-23.86
-22.72
-16.06
-160.96
-25.44
-38.09
-27.72
-127.09
-143.56

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
6,286
6,544
14,281
LT Borrowings
23,068
23,412
16,045
LT Finance Leases
208
178
203
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
48
48
48
Market Capitalization
185,978
128,425
98,221

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
18,356
18,177
17,896
Cash, Cash Equivalents & STI
7,861
7,402
6,129
Accounts Receivable, Net
4,639
5,317
6,699
Inventories
3,707
3,226
3,958
Total Current Liabilities
13,860
14,716
54,043
Payables & Accruals
- -
- -
- -
ST Debt
6,286
6,544
14,281
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.09%
-10.11%
7.68%
Free Cash Flow
34.29%
3.51%
-32.14%
Net Income, GAAP
158.45%
273.62%
316.1%
Sales/Revenue/Turnover
138.69%
92.57%
453.32%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,187
1,360
1,097
- -
4,874
2025
5,955
6,536
6,954
7,522
26,967
2026
8,721
9,535
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-309.36
-37.29
-187.31
- -
-196.63
2025
-211.89
-168.66
-220.96
-403.17
-999.32
2026
-35
-79
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Won-Soo Yoon
Full Time Employees
82
Sector
Health technology
Industry
Medical specialties
Address
96, Mayu-ro Siheung GY South Korea 15111
IPO Date
Nov 28, 2018
Website
tnrbiofab.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
T&R Biofab Co., Ltd. T&R Biofab Co., Ltd. (246710.KQ) develops and commercializes regenerative medical technologies, including 3D-printed medical devices such as bioprinters, bioinks, and bioresorbable scaffolds for tissue and organ regeneration; bio-surgical solutions comprising wound dressings and acellular dermal matrices; and biomaterials and biopharmaceuticals for applications in orthopedics, plastic surgery, dentistry, and drug testing. The company, founded in 2013 and headquartered in Siheung-si, South Korea, operates primarily in the healthcare and biotechnology sectors, targeting medical institutions, pharmaceutical firms, and researchers with customized patient-specific implants and artificial organ models like skin, heart, and liver equivalents. It maintains global ambitions through its proprietary 3D bioprinting platforms, including hybrid bioprinters for hydrogels, polymers, and ceramics, while expanding into adjacent markets such as cosmetics and cultivated meat. Recent developments include the 2024 acquisition of Blisspack, a cosmetics and packaging specialist, for KRW 16.7 billion to synergize tissue regeneration with beauty products; a partnership with CJ CheilJedang Corp. to develop 3D bioprinted alternative meats using its technology; and a collaboration with Ethicon, a Johnson & Johnson subsidiary, to create bioprinted soft tissue scaffolds for wound closure, hernia repair, and reconstructive surgery.